Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

Mayo Clinic, Scottsdale, AZ 85259, USA.
New England Journal of Medicine (Impact Factor: 54.42). 06/2012; 366(23):2171-9. DOI: 10.1056/NEJMoa1113713
Source: PubMed

ABSTRACT Alterations in hedgehog signaling are implicated in the pathogenesis of basal-cell carcinoma. Although most basal-cell carcinomas are treated surgically, no effective therapy exists for locally advanced or metastatic basal-cell carcinoma. A phase 1 study of vismodegib (GDC-0449), a first-in-class, small-molecule inhibitor of the hedgehog pathway, showed a 58% response rate among patients with advanced basal-cell carcinoma.
In this multicenter, international, two-cohort, nonrandomized study, we enrolled patients with metastatic basal-cell carcinoma and those with locally advanced basal-cell carcinoma who had inoperable disease or for whom surgery was inappropriate (because of multiple recurrences and a low likelihood of surgical cure, or substantial anticipated disfigurement). All patients received 150 mg of oral vismodegib daily. The primary end point was the independently assessed objective response rate; the primary hypotheses were that the response rate would be greater than 20% for patients with locally advanced basal-cell carcinoma and greater than 10% for those with metastatic basal-cell carcinoma.
In 33 patients with metastatic basal-cell carcinoma, the independently assessed response rate was 30% (95% confidence interval [CI], 16 to 48; P=0.001). In 63 patients with locally advanced basal-cell carcinoma, the independently assessed response rate was 43% (95% CI, 31 to 56; P<0.001), with complete responses in 13 patients (21%). The median duration of response was 7.6 months in both cohorts. Adverse events occurring in more than 30% of patients were muscle spasms, alopecia, dysgeusia (taste disturbance), weight loss, and fatigue. Serious adverse events were reported in 25% of patients; seven deaths due to adverse events were noted.
Vismodegib is associated with tumor responses in patients with locally advanced or metastatic basal-cell carcinoma. (Funded by Genentech; Erivance BCC number, NCT00833417.).

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Oncoscience 2014, Vol.1, No.9 and genes involved in proliferation/cell cycle regulation, differentiation, self-renewal/stemness, metastasis and survival (for reviews see [3, 6, 18-20]). Suppressor of Fused (SUFU), a key negative regulator of mammalian HH signaling, directly binds to GLIs, thereby preventing their activation and nuclear localization [21]. In addition, proteolytic processing yielding C-terminally truncated GLI repressor forms and proteasome-dependent degradation of GLI proteins constitute critical negative regulatory mechanisms. In this context, phosphorylation of GLIs by protein kinase A (PKA) is a key repressive step in HH/GLI signaling that promotes GLI repressor formation and GLI destabilization [22-36]. Of note, GLI transcription factors can be activated also in a non-canonical SMO independent manner, thereby reversing the therapeutic effect of SMO inhibitors used for targeted inhibition of oncogenic HH signaling [37-52]. The oncogenic role of HH signaling in cancer was first discovered in patients suffering from nevoid basal cell INTRODUCTION
    Oncoscience. 01/2014; 1(9):567-573..
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Gorlin-Goltz syndrome or basal cell nevus syndrome is an autosomal dominant syndrome characterized by skeletal anomalies, numerous cysts observed in the jaw, and multiple basal cell carcinoma of the skin, which may be accompanied by falx cerebri calcification. Basal cell carcinoma is the most commonly skin tumor with slow clinical course and low metastatic potential. Its concomitance with Gorlin syndrome, resulting from a mutation in a tumor suppressor gene, may substantially change morbidity and mortality. A 66-year-old male patient with a history of recurrent basal cell carcinoma was presented with exophthalmus in the left eye and the lesions localized in the left lateral orbita and left zygomatic area. His physical examination revealed hearing loss, gapped teeth, highly arched palate, and frontal prominence. Left orbital mass, cystic masses at frontal and ethmoidal sinuses, and multiple pulmonary nodules were detected at CT scans. Basal cell carcinoma was diagnosed from biopsy of ethmoid sinus. Based on the clinical and typical radiological characteristics (falx cerebri calcification, bifid costa, and odontogenic cysts), the patient was diagnosed with metastatic skin basal cell carcinoma accompanied by Gorlin syndrome. Our case is a basal cell carcinoma with aggressive course accompanying a rarely seen syndrome.
    Case reports in oncological medicine. 01/2014; 2014:362932.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hedgehog (Hh) pathway inhibitors are clinically effective in treatment of basal cell carcinoma and medulloblastoma, but fail therapeutically or accelerate progression in treatment of endodermally derived colon and pancreatic cancers. In bladder, another organ of endodermal origin, we find that despite its initial presence in the cancer cell of origin Sonic hedgehog (Shh) expression is invariably lost during progression to invasive urothelial carcinoma. Genetic blockade of stromal response to Shh furthermore dramatically accelerates progression and decreases survival time. This cancer-restraining effect of Hh pathway activity is associated with stromal expression of BMP signals, which stimulate urothelial differentiation. Progression is dramatically reduced by pharmacological activation of BMP pathway activity with low-dose FK506, suggesting an approach to management of human bladder cancer.
    Cancer cell. 10/2014; 26(4):521-533.

Full-text (2 Sources)

Available from
May 22, 2014